Tyrphostin B44, (+) enantiomerEGFR-kinase inhibitor CAS# 133550-37-5 |
2D Structure
- DCC-2618
Catalog No.:BCC1520
CAS No.:1225278-16-9
- Imatinib Mesylate (STI571)
Catalog No.:BCC1115
CAS No.:220127-57-1
- Sorafenib
Catalog No.:BCN2174
CAS No.:284461-73-0
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- Masitinib (AB1010)
Catalog No.:BCC1260
CAS No.:790299-79-5
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 133550-37-5 | SDF | Download SDF |
PubChem ID | 5328769 | Appearance | Powder |
Formula | C18H16N2O3 | M.Wt | 308.34 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 30 mM in DMSO | ||
Chemical Name | (E)-2-cyano-3-(3,4-dihydroxyphenyl)-N-[(1S)-1-phenylethyl]prop-2-enamide | ||
SMILES | CC(C1=CC=CC=C1)NC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N | ||
Standard InChIKey | UMGQVUWXNOJOSJ-DGGAMASNSA-N | ||
Standard InChI | InChI=1S/C18H16N2O3/c1-12(14-5-3-2-4-6-14)20-18(23)15(11-19)9-13-7-8-16(21)17(22)10-13/h2-10,12,21-22H,1H3,(H,20,23)/b15-9+/t12-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Epidermal growth factor receptor (EGFR) kinase inhibitor (IC50 = 0.86 μM). Slightly less active than the (-) enantiomer. |
Tyrphostin B44, (+) enantiomer Dilution Calculator
Tyrphostin B44, (+) enantiomer Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.2432 mL | 16.2159 mL | 32.4317 mL | 64.8635 mL | 81.0793 mL |
5 mM | 0.6486 mL | 3.2432 mL | 6.4863 mL | 12.9727 mL | 16.2159 mL |
10 mM | 0.3243 mL | 1.6216 mL | 3.2432 mL | 6.4863 mL | 8.1079 mL |
50 mM | 0.0649 mL | 0.3243 mL | 0.6486 mL | 1.2973 mL | 1.6216 mL |
100 mM | 0.0324 mL | 0.1622 mL | 0.3243 mL | 0.6486 mL | 0.8108 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- AG 494
Catalog No.:BCC6722
CAS No.:133550-35-3
- AG 555
Catalog No.:BCC6721
CAS No.:133550-34-2
- Tyrphostin B44, (-) enantiomer
Catalog No.:BCC6703
CAS No.:133550-32-0
- AG-490
Catalog No.:BCC2193
CAS No.:133550-30-8
- Apigenin 4'-O-rhamnoside
Catalog No.:BCN6181
CAS No.:133538-77-9
- Exendin-3 (9-39) amide
Catalog No.:BCC7257
CAS No.:133514-43-9
- SR 1001
Catalog No.:BCC6309
CAS No.:1335106-03-0
- TAI-1
Catalog No.:BCC5576
CAS No.:1334921-03-7
- Fmoc-Glu(OAll)-OH
Catalog No.:BCC3492
CAS No.:133464-46-7
- Iloperidone
Catalog No.:BCC2516
CAS No.:133454-47-4
- Heudelotinone
Catalog No.:BCN6180
CAS No.:133453-58-4
- Angophorol
Catalog No.:BCN3965
CAS No.:133442-54-3
- AG 556
Catalog No.:BCC6720
CAS No.:133550-41-1
- 4,15-Isoatriplicolide methylacrylate
Catalog No.:BCN7935
CAS No.:133559-38-3
- Isoatriplicolide tiglate
Catalog No.:BCN7934
CAS No.:133559-39-4
- Boc-Glutaminol
Catalog No.:BCC3092
CAS No.:133565-42-1
- Boc-Threoninol(Bzl)
Catalog No.:BCC2704
CAS No.:133565-43-2
- Fmoc-Ile-ol
Catalog No.:BCC2584
CAS No.:133565-46-5
- 2-Ethyl-2,6,6-trimethylpiperidin-4-one
Catalog No.:BCN6504
CAS No.:133568-79-3
- 2-Aminoisonicotinic acid
Catalog No.:BCC8550
CAS No.:13362-28-2
- Exoticin
Catalog No.:BCN6182
CAS No.:13364-94-8
- 1-Allyl-3,5-Dimethylpyrazole
Catalog No.:BCC8450
CAS No.:13369-74-9
- GSK 2193874
Catalog No.:BCC8009
CAS No.:1336960-13-4
- Ebenifoline E-II
Catalog No.:BCN3097
CAS No.:133740-16-6
Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases.[Pubmed:1676428]
J Med Chem. 1991 Jun;34(6):1896-907.
We have previously described a novel series of low molecular weight protein tyrosine kinase inhibitors which we named tyrphostins. The characteristic active pharmacophore of these compounds was the hydroxy-cis-benzylidenemalononitrile moiety. In this article we describe three novel groups of tyrphostins: (i) one group has the phenolic moiety of the cis-benzylidenemalononitrile replaced either with other substituted benzenes or with heteroaromatic rings, (ii) another is a series of conformationally constrained derivatives of hydroxy-cis-benzylidenemalononitriles in which the malononitrile moiety is fixed relative to the aromatic ring, and (iii) two groups of compounds in which the position trans to the benzenemalononitrile has been substituted by ketones and amides. Among the novel tyrphostins examined we found inhibitors which discriminate between the highly homologous EGF receptor kinase (HER1) and ErbB2/neu kinase (HER2). These findings may lead to selective tyrosine kinase blockers for the treatment of diseases in which ErbB2/neu is involved.